MD Labs, the makers of the Rxight genetic testing panel, recently announced that the U.S. Food and Drug Administration warns that ADHD medications can cause adverse psychiatric effects and that the Rxight genetic testing can help patients better assess prescription drugs. Read More »

Amgen's data from two studies shows that for appropriate patients in the United States, the majority of prescription claims for PCSK9 inhibitors, such as Repatha (evolocumab), were initially rejected. Read More »

Biologics Inc., an oncology pharmacy services company owned by McKesson Specialty Health, was selected by Novartis to be a specialty pharmacy provider for KISQALI (ribociclib). Read More »

Alkermes PLC will present data for the two-month dosing option of ARISTADA (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia at the 16th International Congress on Schizophrenia Research in San Diego Friday through Monday. Read More »

Amgen recently announced the results of the Repatha (evolocumab) cognitive function trial that examined cognitive function for 1,974 patients enrolled in the Repatha cardiovascular outcomes study. Read More »

Mylan N.V. recently announced that it settled a case relating to patents for Herceptin, from Genentech Inc. and F. Hoffman-La Roche Ltd., giving Mylan global licenses for its trastuzumab product. Read More »

Allergan and Editas Medicine have entered a strategic research and development alliance that gives Allergan exclusive access and the option to license up to five of Editas Medicine’s genome-editing ocular programs. Read More »

Amgen's positive results from a planned overall survival interim analysis of the Phase 3 head-to-head ENDEAVOR trial. Read More »

Diplomat Pharmacy Inc. recently announced that it will dispense KISQALI as a first-line treatment for postmenopausal women with serious forms of breast cancer. Read More »

Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC recently entered a licensing agreement that will give MainPointe exclusive marketing rights for NEXAFED and NEXAFED Sinus in the United States and Canada. Read More »

Regeneron and Sanofi are set to present new data from the Phase 3 Praluent (alirocumab) injection clinical trial program at this weekend’s American College of Cardiology Scientific Sessions (ACC 17) in Washington, D.C. Read More »

Amgen’s recent Phase 3 study of the effects of Repatha on patients who receive apheresis for low-density lipoprotein cholesterol showed a promising reduction in the need for the recurring procedure. Read More »

The American Society of Health-System Pharmacists recently released “The Effective Pharmacy Preceptor,” a reference to assist pharmacists in training students and residents through experiential education techniques. Read More »

Pfizer Inc. is renewing its partnership with the Union for International Cancer Control through a grant of $530,000 for the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge. Read More »

Pernix Therapeutics Holdings Inc. recently announced that it has been given positive feedback on its litigation in regards to the proposed generic version of Zohydro ER with Actavis Laboratories FL Inc. Read More »

Bristol-Myers Squibb Co. and Pfizer Inc. will present eight of their abstracts at the American College of Cardiology's 66th Annual Scientific Session in Washington, D.C. March 17-19. Read More »

Amgen's results of its Repatha (evolocumab) cardiovascular outcomes trial will be released at the American College of Cardiology's 66th Annual Scientific Session, which is set to take place in Washington, D.C. March 17-19. Read More »

CVS Health has selected Epic as its new electronic health record system for its more specialized care program, CVS Specialty, which includes Accordant, a care management program available to individuals suffering from rare diseases. Read More »

Following a precautionary hold on the dosing of an FAAH inhibitor, Janssen has again begun its clinical research of this investigational medication in two Phase 2 studies.  Read More »

Sandoz, a Novartis division, has released data for its proposed biosimilar adalimumab (GP2017). Read More »